These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 24243140)

  • 1. The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
    Curtis NJ; Noble F; Bailey IS; Kelly JJ; Byrne JP; Underwood TJ
    J Surg Oncol; 2014 Mar; 109(3):202-7. PubMed ID: 24243140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
    Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
    World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma.
    Mitchell KG; Ikoma N; Nelson DB; Maru DM; Erasmus JJ; Weston BR; Vaporciyan AA; Antonoff MB; Mehran RJ; Rice DC; Roth JA; Swisher SG; Sepesi B; Walsh GL; Correa AM; Das P; Blum MA; Badgwell BD; Hofstetter WL
    Ann Thorac Surg; 2019 Sep; 108(3):845-851. PubMed ID: 31102632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 5. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
    Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
    Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in prognosis of Siewert II and III oesophagogastric junction cancers are determined by the baseline tumour staging but not its anatomical location.
    Kulig P; Sierzega M; Pach R; Kolodziejczyk P; Kulig J;
    Eur J Surg Oncol; 2016 Aug; 42(8):1215-21. PubMed ID: 27241921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proximal margin length with transhiatal gastrectomy for Siewert type II and III adenocarcinomas of the oesophagogastric junction.
    Mine S; Sano T; Hiki N; Yamada K; Kosuga T; Nunobe S; Yamaguchi T
    Br J Surg; 2013 Jul; 100(8):1050-4. PubMed ID: 23754647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse-Type Histology Is Prognostic for All Siewert Types of Gastroesophageal Adenocarcinoma.
    Mahuron KM; Sullivan KM; Hernandez MC; Chen YJ; Chao J; Melstrom LG; Paz IB; Kim JY; Mannan R; Lin JL; Fong Y; Woo Y
    J Gastric Cancer; 2024 Jul; 24(3):267-279. PubMed ID: 38960886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Survival comparison of Siewert II adenocarcinoma of esophagogastric junction between transthoracic and transabdominal approaches:a joint data analysis of thoracic and gastrointestinal surgery].
    Yang S; Yuan Y; Hu H; Li R; Liu K; Zhang W; Yang K; Yang Y; Bai D; Chen X; Zhou Z; Chen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):132-142. PubMed ID: 30799535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
    Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
    World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Staging and outcome depending on surgical treatment in adenocarcinomas of the oesophagogastric junction.
    Reeh M; Mina S; Bockhorn M; Kutup A; Nentwich MF; Marx A; Sauter G; Rösch T; Izbicki JR; Bogoevski D
    Br J Surg; 2012 Oct; 99(10):1406-14. PubMed ID: 22961520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.
    Alderson D; Cunningham D; Nankivell M; Blazeby JM; Griffin SM; Crellin A; Grabsch HI; Langer R; Pritchard S; Okines A; Krysztopik R; Coxon F; Thompson J; Falk S; Robb C; Stenning S; Langley RE
    Lancet Oncol; 2017 Sep; 18(9):1249-1260. PubMed ID: 28784312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
    Waddell T; Chau I; Cunningham D; Gonzalez D; Okines AF; Okines C; Wotherspoon A; Saffery C; Middleton G; Wadsley J; Ferry D; Mansoor W; Crosby T; Coxon F; Smith D; Waters J; Iveson T; Falk S; Slater S; Peckitt C; Barbachano Y
    Lancet Oncol; 2013 May; 14(6):481-9. PubMed ID: 23594787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
    Rivera F; Izquierdo-Manuel M; García-Alfonso P; Martínez de Castro E; Gallego J; Limón ML; Alsina M; López L; Galán M; Falcó E; Manzano JL; González E; Muñoz-Unceta N; López C; Aranda E; Fernández E; Jorge M; Jiménez-Fonseca P
    Eur J Cancer; 2021 Mar; 145():158-167. PubMed ID: 33485079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of the superiority of different TNM staging systems in Siewert III adenocarcinoma of esophagogastric junction].
    Lu Y; Xi H; Xie T; Qiu Z; Wang X; Wei B; Chen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):143-148. PubMed ID: 30799536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.
    Noble F; Lloyd MA; Turkington R; Griffiths E; O'Donovan M; O'Neill JR; Mercer S; Parsons SL; Fitzgerald RC; Underwood TJ;
    Br J Surg; 2017 Dec; 104(13):1816-1828. PubMed ID: 28944954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
    Cunningham D; Okines AF; Ashley S
    N Engl J Med; 2010 Mar; 362(9):858-9. PubMed ID: 20200397
    [No Abstract]   [Full Text] [Related]  

  • 19. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary outcomes for resected type 1-3 gastroesophageal junction adenocarcinoma: a single-center experience.
    Stiles ZE; Hagerty BL; Brady M; Mukherjee S; Hochwald SN; Kukar M
    J Gastrointest Surg; 2024 May; 28(5):634-639. PubMed ID: 38704200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.